[ad_1] Anti-obesity drugmakers Novo Nordisk and Eli Lilly have a huge lead on their competition, but given the vast and valuable market, rivals are still eager to join the race. Bank of America analyst Geoff Meacham has been very bullish about the opportunity, which he calls “unprecedented” given the prevalence of obesity and the huge…
[ad_1] Health care may be a real challenger to tech this year, a business that can actually grow faster than most of tech and has the possibility of a comeback from the Covid straitjacket that so many of these companies got caught up in. The pandemic obscured so much of the growth as Abbott Labs…
[ad_1] There’s an opportunity for investors in pharmaceuticals that’s been “underrepresented for a very long time,” according to fund manager Philip Ripman of Storebrand Asset Management. The area is women’s healthcare, according to Ripman, who manages the $1 billion Storebrand Global Solutions fund. “Within the portfolio, the aspect that we’ve really focused in on is…
